HCPCS Level II
Q5160
Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg
Codes near Q5160
These sit next to Q5160 in the CMS Level II file. All Q codes
- Q5155Injection, aflibercept-jbvf (yesafili), biosimilar, 1 mg
- Q5156Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
- Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg
- Q5158Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg
- Q5159Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg
- Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
- Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
- Q5164Injection, ustekinumab-hmny (starjemza), biosimilar, 1 mg
- Q5165Injection, denosumab-mobz (oziltus), biosimilar, 1 mg
- Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 83257-0009-11 | Jobevne | Biocon Biologics Inc. | 10 |
| 83257-0010-11 | Jobevne | Biocon Biologics Inc. | 40 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.